Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Debashis Sarker
Delayed Adverse Events in Phase I Trials of Molecularly Targeted and Cytotoxic Agents
Oncotarget
Oncology
Chronic Inflammation Markers Are Associated With Risk of Pancreatic Cancer in the Swedish AMORIS Cohort Study
BMC Cancer
Cancer Research
Oncology
Genetics
Related publications
Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?
British Journal of Cancer
Cancer Research
Oncology
Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination
Clinical Cancer Research
Cancer Research
Oncology
A Bayesian Dose Finding Design for Clinical Trials Combining a Cytotoxic Agent With a Molecularly Targeted Agent
Journal of the Royal Statistical Society. Series C: Applied Statistics
Uncertainty
Statistics
Probability
Correction: Article on the Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II Trials
Clinical Cancer Research
Cancer Research
Oncology
Prognostic and Predictive Factors Associated With Ipilimumab-Related Adverse Events: A Retrospective Analysis of 11 NCI-sponsored Phase I Clinical Trials
Oncotarget
Oncology
JS4-2Molecular Targeting Agents and Cardiovascular Adverse Events
Annals of Oncology
Medicine
Oncology
Hematology
Advances in the Study of Molecularly Targeted Agents to Treat Hepatocellular Carcinoma
Drug discoveries & therapeutics
Medicine
Toxicology
Pharmaceutics
Pharmacology
Inappropriate Grading of Adverse Events in Cancer Clinical Trials—Reply
JAMA Oncology
Cancer Research
Oncology
Lipoprotein(a) Reductions From PCSK9 Inhibition and Major Adverse Cardiovascular Events: Pooled Analysis of Alirocumab Phase 3 Trials
Atherosclerosis
Cardiovascular Medicine
Cardiology
